← All verdicts
Verdict

Data Unavailable

Every analyzed stock in Data Unavailable — 2,921 companies. Each card shows price, our model's intrinsic value (IV), and how far price sits above or below it. Click any card for the full analysis. This is a research-triage view, not a buy/sell signal.

Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
"Data Unavailable" by: Model value (price vs DCF) Owner-earnings return (equity bond)

This lens: price against our probability-weighted DCF value (P/IV). Its own forward record began accruing on 2026-09-10 (daily snapshots); until a year of it exists, the panel below tests the nearest cousin we can measure point-in-time — cheap on book value — and says so.

Market state today: Calm — the S&P 500 closed 3.1% below its 1-year high (as of 2026-09-16). Our rule, the same one used to split every backtest on this site: sell-off = 10% or more below the 1-year high, borderline from 5%, calm otherwise. A further 7.2% fall from here would put us in a sell-off. Since 2006 the market has been in a sell-off 16.6% of the time, across 13 episodes (red bands).
2007200920112013201520172019202120232025
S&P 500 (SPY, adjusted) distance from its trailing 1-year high, weekly. Amber band: borderline (−5% to −10%). Red band: sell-off (below −10%). The dot is today. History to 2026-08-19 from the research database; today from the live feed.
Backtest · point in time · 8,702 entries in the study

Does this screen work? The record for exactly these filters

Screen tested: Proxy: price-to-book ≤ 1.2 (undervalued band has no point-in-time history yet) · bought the day of the annual report, held 12 months
Probable Buy every company that met this screen on the day it filed its annual report, hold 12 months: on average it beat the S&P 500 by +12.6 pts (1,427 entries, 311 companies, very unlikely to be luck). 50% of entries beat the S&P; 25% beat it by 30 points or more; 30% trailed it by 20 points or more. Owning everything instead averaged +1.7 pts, so the screen's edge is +10.9 pts.
+12.6 ptsvs S&P, average
50%beat the S&P
25%up 30+ pts vs S&P
30%down 20+ pts vs S&P
+14.0 ptsvs small caps, 12 mo
−15.1 pts 2019worst year to buy ?
6.1luck check ?
Does the holding period matter?3 mo: +2.3 pts 49% beat6 mo: +4.6 pts 49% beat12 mo: +12.6 pts 50% beat24 mo: +21.8 pts 46% beat3 yr, per yr: +1.3 pts 40% beat
Market state at entryCompany-yearsvs S&P 12 movs small caps
Calm ◀ today1,245+7.9 pts t 4.6+10.1 pts
Sell-off (S&P ≥10% off high)182+44.5 pts t 4.0+40.7 pts
Sector (SEC group)nvs S&P 12 mo3 yrs / yr
Industrials & manufacturing466+13.0 pts t 4.0−2.2 pts
Energy126+7.4 pts t 1.2−7.8 pts
Other115+8.4 pts t 1.8+3.8 pts
Tech hardware & semis113+10.9 pts t 1.6+2.3 pts
Services96+11.9 pts t 2.7+12.2 pts
Retail & consumer87+17.2 pts t 2.1+10.2 pts
Finance & real estate72−1.7 pts t -0.5−2.4 pts
Utilities65+5.6 pts t 0.6−1.2 pts
Construction53+13.2 pts t 1.7−2.4 pts
Biotech & pharma44+47.1 pts t 1.6+10.0 pts
Telecom & media43+14.0 pts t 0.7−6.3 pts
Software & IT services35+39.9 pts t 1.8+1.2 pts

Holds up out of sample? Before 2018: +10.7 pts (n 629, t 6.0). From 2018: +14.0 pts (n 798, t 4.1). Same sign in both halves.

Year2010201120122013201420152016201720182019202020212022202320242025
vs S&P+13 pts+5 pts+14 pts+18 pts−4 pts−4 pts+22 pts+12 pts−3 pts−15 pts+87 pts+8 pts+17 pts−9 pts−7 pts+15 pts
n254310610178841118178991297276108121115

Read the research behind this screen: Price-to-book still sorts, across all sizes → · Test your own combination in the Screen Lab →

Our model values are recomputed daily but were never stored historically, so this band cannot be backtested honestly yet. Daily snapshots began 2026-09-10; a true record accrues from there. Until then the nearest tested cousin is shown — cheap on book value — and labelled as a proxy. Point-in-time: each entry is one company bought at the first close after its 10-K filing date, using only filings available that day, held 12 months; result = total return minus SPY over the same months (vs IWM for 12 months; 3-yr annualised). Survivorship-tilted universe; no costs; read spreads, not levels. Educational, hypothetical, before costs.

Sort by: A–Z Riskiest Most overvalued Most shorted Buyers' strike Largest
AAAU
Goldman Sachs Physical Gold ETF
Valuation N/A
Financial Services Risk 32 · Moderate
Price$42.36
Model IV—
P/IV—
Limited data — see page
AACB
Artius II Acquisition Inc.
Valuation N/A
Financial Services
Price$10.59
Model IV—
P/IV—
Limited data — see page
AACBR
Artius II Acquisition Inc.
Valuation N/A
Financial Services
Price$0.01
Model IV—
P/IV—
Limited data — see page
AACG
ATA Creativity Global
Valuation N/A
Consumer Defensive Risk 44 · Elevated
Price$0.86
Model IV—
P/IV—
Market implies +21.7%/yr vs model +4.8% · above model
AACI
Armada Acquisition Corp. III
Valuation N/A
Financial Services
Price$10.05
Model IV—
P/IV—
Limited data — see page
AACO
Abony Acquisition Corp. I
Valuation N/A
Financial Services
Price$9.99
Model IV—
P/IV—
Limited data — see page
AACP
Apogee Acquisition Corp
Valuation N/A
Financial Services
Price$10.06
Model IV—
P/IV—
Limited data — see page
AAMI
Acadian Asset Management Inc.
Valuation N/A
Financial Services Risk 60 · High
Price$91.02
Model IV—
P/IV—
Market implies +38.0%/yr vs model +2.0% · above model
AAOI
APPLIED OPTOELECTRONICS, INC.
Valuation N/A
Technology Risk 37 · Moderate
Price$95.29
Model IV—
P/IV—
Market implies +44.9%/yr vs model +21.2% · above model
AAON
AAON, INC.
Valuation N/A
Industrials Risk 49 · Elevated
Price$79.80
Model IV—
P/IV—
Market implies +18.6%/yr vs model +28.2% · below model
AAPG
ASCENTAGE PHARMA GROUP INTERNATIONAL
Valuation N/A
Healthcare Risk 37 · Moderate
Price$16.00
Model IV—
P/IV—
Limited data — see page
AARD
Aardvark Therapeutics, Inc.
Valuation N/A
Healthcare Risk 27 · Moderate
Price$5.02
Model IV—
P/IV—
Limited data — see page
AAUC
Allied Gold Corp
Valuation N/A
Unknown Risk 37 · Moderate
Price$21.10
Model IV—
P/IV—
Limited data — see page
ABCL
AbCellera Biologics Inc.
Valuation N/A
Healthcare Risk 34 · Moderate
Price$10.89
Model IV—
P/IV—
Market implies +107.9%/yr vs model +2.0% · above model
ABEO
ABEONA THERAPEUTICS INC.
Valuation N/A
Healthcare Risk 44 · Elevated
Price$5.47
Model IV—
P/IV—
Market implies +52.4%/yr vs model +18.0% · above model
ABEV
AMBEV S.A.
Valuation N/A
Consumer Defensive Risk 46 · Elevated
Price$3.03
Model IV—
P/IV—
Limited data — see page
ABOS
Acumen Pharmaceuticals, Inc.
Valuation N/A
Healthcare Risk 44 · Elevated
Price$2.89
Model IV—
P/IV—
Limited data — see page
ABSI
Absci Corp
Valuation N/A
Industrials Risk 27 · Moderate
Price$8.21
Model IV—
P/IV—
Market implies +112.3%/yr vs model +2.0% · above model
ABUS
Arbutus Biopharma Corp
Valuation N/A
Healthcare Risk 42 · Elevated
Price$5.06
Model IV—
P/IV—
Market implies +84.2%/yr vs model +2.0% · above model
ABVC
ABVC BIOPHARMA, INC.
Valuation N/A
Healthcare Risk 27 · Moderate
Price$0.98
Model IV—
P/IV—
Market implies +61.4%/yr vs model +2.0% · above model
ABVE
Above Food Ingredients Inc.
Valuation N/A
Consumer Defensive
Price$0.11
Model IV—
P/IV—
Limited data — see page
ABVX
Abivax S.A.
Valuation N/A
Healthcare Risk 46 · Elevated
Price$106.66
Model IV—
P/IV—
Limited data — see page
ACAA
Averin Capital Acquisition Corp.
Valuation N/A
Financial Services
Price$9.98
Model IV—
P/IV—
Limited data — see page
ACB
AURORA CANNABIS INC
Valuation N/A
Healthcare Risk 55 · Elevated
Price$3.82
Model IV—
P/IV—
Limited data — see page
ACET
Adicet Bio, Inc.
Valuation N/A
Healthcare Risk 27 · Moderate
Price$9.52
Model IV—
P/IV—
Limited data — see page
ACGC
ACP Holdings Acquisition Corp.
Valuation N/A
Financial Services
Price$10.04
Model IV—
P/IV—
Limited data — see page
ACHR
Archer Aviation Inc.
Valuation N/A
Industrials Risk 30 · Moderate
Price$5.58
Model IV—
P/IV—
Market implies +150.0%/yr vs model +15.0% · above model
ACHV
ACHIEVE LIFE SCIENCES, INC.
Valuation N/A
Healthcare Risk 37 · Moderate
Price$7.06
Model IV—
P/IV—
Limited data — see page
ACIU
AC Immune SA
Valuation N/A
Healthcare Risk 55 · Elevated
Price$2.76
Model IV—
P/IV—
Limited data — see page
ACMR
ACM Research, Inc.
Valuation N/A
Industrials Risk 41 · Elevated
Price$72.00
Model IV—
P/IV—
Market implies +31.4%/yr vs model +36.5% · below model
ACOG
Alpha Cognition Inc.
Valuation N/A
Healthcare Risk 40 · Elevated
Price$8.71
Model IV—
P/IV—
Market implies +29.7%/yr vs model +15.0% · above model
ACON
Aclarion, Inc.
Valuation N/A
Healthcare Risk 39 · Moderate
Price$2.60
Model IV—
P/IV—
Market implies +32.0%/yr vs model +5.9% · above model
ACP
abrdn Income Credit Strategies Fund
Valuation N/A
Unknown
Price$4.57
Model IV—
P/IV—
Limited data — see page
ACRS
Aclaris Therapeutics, Inc.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$5.32
Model IV—
P/IV—
Market implies +36.1%/yr vs model +3.7% · above model
ACRV
Acrivon Therapeutics, Inc.
Valuation N/A
Healthcare Risk 39 · Moderate
Price$2.00
Model IV—
P/IV—
Limited data — see page
ACTU
ACTUATE THERAPEUTICS, INC.
Valuation N/A
Healthcare Risk 42 · Elevated
Price$1.07
Model IV—
P/IV—
Limited data — see page
ACV
Virtus Diversified Income & Convertible Fund
Valuation N/A
Unknown
Price$26.13
Model IV—
P/IV—
Limited data — see page
ACXP
Acurx Pharmaceuticals, Inc.
Valuation N/A
Healthcare Risk 33 · Moderate
Price$1.40
Model IV—
P/IV—
Limited data — see page
ADAC
American Drive Acquisition Co
Valuation N/A
Financial Services
Price$10.09
Model IV—
P/IV—
Limited data — see page
ADAG
Adagene Inc.
Valuation N/A
Healthcare Risk 40 · Elevated
Price$3.40
Model IV—
P/IV—
Market implies +45.1%/yr vs model +2.0% · above model
ADCT
ADC Therapeutics SA
Valuation N/A
Healthcare Risk 41 · Elevated
Price$1.11
Model IV—
P/IV—
Market implies +11.9%/yr vs model +15.0% · below model
ADGM
Adagio Medical Holdings, Inc.
Valuation N/A
Healthcare Risk 49 · Elevated
Price$0.56
Model IV—
P/IV—
Market implies +42.8%/yr vs model +15.0% · above model
ADIL
ADIAL PHARMACEUTICALS, INC.
Valuation N/A
Healthcare Risk 29 · Moderate
Price$4.90
Model IV—
P/IV—
Limited data — see page
ADPT
Adaptive Biotechnologies Corp
Valuation N/A
Healthcare Risk 40 · Elevated
Price$24.20
Model IV—
P/IV—
Market implies +40.7%/yr vs model +15.7% · above model
ADSE
Ads-Tec Energy Public Ltd Co
Valuation N/A
Technology Risk 32 · Moderate
Price$11.17
Model IV—
P/IV—
Limited data — see page
ADT
ADT Inc.
Valuation N/A
Technology
Price$7.05
Model IV—
P/IV—
Limited data — see page
ADUR
ADURO CLEAN TECHNOLOGIES INC.
Valuation N/A
Basic Materials Risk 54 · Elevated
Price$12.90
Model IV—
P/IV—
Limited data — see page
ADV
Advantage Solutions Inc.
Valuation N/A
Technology Risk 67 · High
Price$33.32
Model IV—
P/IV—
Market implies +43.8%/yr vs model +3.3% · above model
ADVB
Advanced Biomed Inc.
Valuation N/A
Healthcare Risk 44 · Elevated
Price$8.19
Model IV—
P/IV—
Limited data — see page
ADX
ADAMS DIVERSIFIED EQUITY FUND, INC.
Valuation N/A
Unknown
Price$25.80
Model IV—
P/IV—
Limited data — see page
ADXN
Addex Therapeutics Ltd.
Valuation N/A
Healthcare Risk 41 · Elevated
Price$3.26
Model IV—
P/IV—
Limited data — see page
AEAQ
Activate Energy Acquisition Corp.
Valuation N/A
Financial Services
Price$10.08
Model IV—
P/IV—
Limited data — see page
AEC
ANFIELD ENERGY INC.
Valuation N/A
Basic Materials
Price$3.96
Model IV—
P/IV—
Limited data — see page
AEF
abrdn Emerging Markets ex-China Fund, Inc.
Valuation N/A
Unknown
Price$9.92
Model IV—
P/IV—
Limited data — see page
AEFC
AEGON LTD.
Valuation N/A
Financial Services
Price$17.90
Model IV—
P/IV—
Limited data — see page
AEG
AEGON LTD.
Valuation N/A
Financial Services
Price$9.06
Model IV—
P/IV—
Limited data — see page
AEHL
Antelope Enterprise Holdings Ltd
Valuation N/A
Communication Services Risk 39 · Moderate
Price$7.81
Model IV—
P/IV—
Limited data — see page
AEHR
AEHR TEST SYSTEMS
Valuation N/A
Healthcare Risk 55 · Elevated
Price$83.37
Model IV—
P/IV—
Market implies +56.5%/yr vs model +37.3% · above model
AEI
Alset Inc.
Valuation N/A
Real Estate Risk 52 · Elevated
Price$1.01
Model IV—
P/IV—
Market implies +30.8%/yr vs model +2.0% · above model
AEIS
ADVANCED ENERGY INDUSTRIES INC
Valuation N/A
Technology Risk 49 · Elevated
Price$254.35
Model IV—
P/IV—
Market implies +27.3%/yr vs model +5.4% · above model